Filing Flows › Comparisons › EOLS vs ARWR
Evolus vs Arrowhead Pharmaceuticals: EOLS and ARWR compared
Evolus is the larger company: $78.0M of revenue in its latest quarter (Q3 2026) against $75.3M for Arrowhead Pharmaceuticals (Q3 FY26). Arrowhead Pharmaceuticals is growing faster (+171% against +13% a year earlier). Evolus is more profitable, with an operating margin of -10.8% against -226.0%.
Where the money goes: EOLS and ARWR
Evolus (EOLS) · Q3 2026
Evolus, Q3 2026: revenue $78.0M (+13% year over year), operating margin -10.8%, net loss $12.5M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
Arrowhead Pharmaceuticals (ARWR) · Q3 FY26
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart follows the revenue to costs, profit and cash.
| Evolus (EOLS) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 FY26 |
| Revenue | $78.0M | $75.3M |
| Revenue growth, Y/Y | +13% | +171% |
| Operating margin | -10.8% | -226.0% |
| Net earnings | −$12.5M | −$179M |
| Net margin | -16.1% | -237.8% |
| Operating cash flow | −$1.9M | −$177M |
Where the revenue comes from
Evolus
- Product revenue, net: $77.2M (99%)
- Service revenue: $741K (1%)
Questions
Which is bigger, Evolus or Arrowhead Pharmaceuticals?
Evolus is the larger company: $78.0M of revenue in its latest quarter (Q3 2026) against $75.3M for Arrowhead Pharmaceuticals (Q3 FY26).
Is Evolus or Arrowhead Pharmaceuticals growing faster?
Arrowhead Pharmaceuticals is growing faster (+171% against +13% a year earlier).
Which is more profitable, Evolus or Arrowhead Pharmaceuticals?
Evolus is more profitable, with an operating margin of -10.8% against -226.0%.
More: Evolus earnings · how Evolus makes money · Arrowhead Pharmaceuticals earnings · how Arrowhead Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 4, 2026). Fiscal quarters can end on different dates. Not investment advice.